Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug 22:5:402.
doi: 10.1186/1752-1947-5-402.

Glucagonoma syndrome: a case report

Affiliations

Glucagonoma syndrome: a case report

Pablo Granero Castro et al. J Med Case Rep. .

Abstract

Introduction: Glucagonoma syndrome is a rare paraneoplastic phenomenon, with an estimated incidence of one in 20 million, characterized by necrolytic migratory erythema, hyperglucagonemia, diabetes mellitus, anemia, weight loss, glossitis, cheilitis, steatorrhea, diarrhea, venous thrombosis and neuropsychiatric disturbances in the setting of a glucagon-producing alpha-cell tumor of the pancreas. Necrolytic migratory erythema is the presenting manifestation in the majority of cases, so its early suspicion and correct diagnosis is a key factor in the management of the patient.

Case presentation: We present the case of a 70-year-old Caucasian woman with glucagonoma syndrome due to an alpha-cell tumor located in the tail of the pancreas, successfully treated with surgical resection.

Conclusion: Clinicians should be aware of the unusual initial manifestations of glucagonoma. Early diagnosis allows complete surgical resection of the neoplasm and provides the only chance of a cure.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Necrolytic migratory erythema. (A) Skin lesions affecting pretibial area. (B) Skin biopsy in necrolytic migratory erythema showing a zone of necrolysis and vacuolated keratinocytes.
Figure 2
Figure 2
Radiological and histological findings. (A) Axial and (B) coronal CT scan revealing a 5-7 cm nodular mass in the tail of her pancreas (*)(C) Histological examination of the mass showing an alpha-cell pancreatic tumor (hematoxylin and eosin ×20). (D) Inmunostaining revealed numerous glucagon-positive cells (×20).

References

    1. Hellman P, Andersson M, Rastad J, Juhlin C, Karacagil S, Eriksson B, Skogseid B, Akerström G. Surgical strategy for large or malignant endocrine pancreatic tumors. World J Surg. 2000;24:1353–1360. doi: 10.1007/s002680010224. - DOI - PubMed
    1. Okauchi Y, Nammo T, Iwahashi H, Kizu T, Hayashi I, Okita K, Yamagata K, Uno S, Katsube F, Matsuhisa M, Kato K, Aozasa K, Kim T, Osuga K, Nakamori S, Tamaki Y, Funahashi T, Miyagawa J, Shimomura I. Glucagonoma diagnosed by arterial stimulation and venous sampling (ASVS) Inter Med. 2009;48:1025–1030. doi: 10.2169/internalmedicine.48.1676. - DOI - PubMed
    1. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine. 1996;75:53–63. doi: 10.1097/00005792-199603000-00002. - DOI - PubMed
    1. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci. 2001;321:306–320. doi: 10.1097/00000441-200105000-00003. - DOI - PubMed
    1. Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev. 1981;2:347–361. doi: 10.1210/edrv-2-3-347. - DOI - PubMed

LinkOut - more resources